Lower doses, same hope? new trial aims to tame myeloma with fewer side effects
NCT ID NCT05145400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests a combination of three drugs—isatuximab, lenalidomide, and dexamethasone—at lower doses than usual for people newly diagnosed with multiple myeloma who are at high risk for side effects. The goal is to see if the treatment can still control the cancer while being easier to tolerate. About 50 participants will be enrolled, and the main measure of success is how many patients achieve at least a partial response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isatuximab, lenalidomide, and dexamethasone
What this could lead to
If successful, this could show that lower doses of these drugs effectively control multiple myeloma while reducing harsh side effects for vulnerable patients.
What could go wrong
This is a small, early-phase trial with only 50 participants. Lower doses may not control the cancer as well, and side effects could still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke Comprehensive Cancer Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
-
Novant Health New Hanover Regional Medical Center
RECRUITINGWilmington, North Carolina, 28401, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
-
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact